Baker Institute director Edward P. Djerejian, former ambassador to Israel and to Syria, appeared on Al-Jazeera's "From Washington"
program to discuss the possible consequences of Jamal Khashoggi's disappearance (Arabic): https://youtu.be/J7-xALrG_3s.
Baker Institute director Edward P. Djerejian comments on a welcome moment of nonpartisanship after the April 21, 2018, funeral for former first lady Barbara Bush.
James A. Baker, III, and George P. Shultz — both former secretaries of state and Treasury secretaries — offer "A Conservative Answer to Climate Change" in a commentary for The Wall Street Journal.
James A. Baker, III, George P. ShulzFebruary 15, 2017
High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.
In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.
It is inconceivable to imagine our nation today without the gains of the Civil Rights Act. It is impossible to understand why the issue was so divisive then, since it is such an obvious right and moral proposition. Similarly, let us hope we will look back at the Affordable Care Act 20 years from now and wonder why it was such a contentious topic in 2014.
Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.
Baker Institute health policy experts Hagop M. Kantarjian and Vivian Ho explain why Texas, which holds the notorious record of the highest rate of uninsured citizens in the U.S., should follow many Republican-led states that are now reconsidering the Medicaid expansion program under Obamacare.